Candriam S.C.A. Buys 3,464 Shares of Veeva Systems Inc. $VEEV

Candriam S.C.A. increased its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 1.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 258,784 shares of the technology company’s stock after purchasing an additional 3,464 shares during the quarter. Candriam S.C.A. owned about 0.16% of Veeva Systems worth $77,094,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of VEEV. Vanguard Group Inc. boosted its position in Veeva Systems by 1.4% in the 2nd quarter. Vanguard Group Inc. now owns 14,971,425 shares of the technology company’s stock valued at $4,311,471,000 after buying an additional 210,859 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Veeva Systems by 3.7% during the second quarter. Alliancebernstein L.P. now owns 5,705,648 shares of the technology company’s stock valued at $1,643,113,000 after acquiring an additional 205,997 shares during the period. Principal Financial Group Inc. boosted its holdings in Veeva Systems by 11.2% in the third quarter. Principal Financial Group Inc. now owns 3,846,877 shares of the technology company’s stock valued at $1,146,040,000 after acquiring an additional 388,864 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Veeva Systems by 2.6% in the second quarter. JPMorgan Chase & Co. now owns 3,316,274 shares of the technology company’s stock valued at $955,030,000 after acquiring an additional 85,516 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Veeva Systems by 3.8% in the second quarter. Geode Capital Management LLC now owns 3,092,539 shares of the technology company’s stock worth $888,108,000 after purchasing an additional 114,003 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

Insider Activity

In other news, insider Thomas D. Schwenger sold 1,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total value of $231,430.00. Following the sale, the insider directly owned 23,204 shares in the company, valued at $5,370,101.72. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 10.30% of the stock is owned by corporate insiders.

Veeva Systems Stock Performance

Shares of VEEV opened at $183.63 on Monday. The firm has a market cap of $30.19 billion, a P/E ratio of 35.73, a PEG ratio of 1.27 and a beta of 1.08. Veeva Systems Inc. has a twelve month low of $177.88 and a twelve month high of $310.50. The firm’s 50 day moving average price is $222.33 and its two-hundred day moving average price is $261.25.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Thursday, November 20th. The technology company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.09. The company had revenue of $0.81 million during the quarter, compared to the consensus estimate of $792.37 million. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The firm’s revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.75 earnings per share. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. On average, sell-side analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Veeva Systems announced that its board has approved a stock buyback plan on Monday, January 5th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the technology company to buy up to 5.5% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

VEEV has been the topic of a number of research reports. William Blair restated an “outperform” rating on shares of Veeva Systems in a research report on Friday, October 17th. UBS Group cut their price objective on shares of Veeva Systems from $310.00 to $280.00 and set a “neutral” rating on the stock in a report on Friday, November 21st. BMO Capital Markets began coverage on shares of Veeva Systems in a research note on Thursday, November 13th. They issued a “market perform” rating and a $300.00 price objective on the stock. Wells Fargo & Company dropped their target price on shares of Veeva Systems from $341.00 to $333.00 and set an “overweight” rating for the company in a research report on Tuesday, November 25th. Finally, The Goldman Sachs Group assumed coverage on Veeva Systems in a research note on Tuesday, January 13th. They issued a “sell” rating and a $215.00 price target on the stock. Eighteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $308.04.

Veeva Systems Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.